![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
home.att.net Today LGND made a major announcement at the Bear Stearns' Biotech conference this morning. One of LGND's retinoids, Targretin, is in advanced clinical trials for a wide range of cancers. Today LGND indicated that pre-clinical data (in mice and rats) suggested additional indications (for type II diabetes and breast cancer). Over 1/2 million shares traded in the first hour and the price has moved to 15 1/4 (from yesterday's close of 13 1/8). Henry N Fox Chapel | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |